175 related articles for article (PubMed ID: 32228842)
1. [Segmental overgrowth syndromes and therapeutic strategies].
Venot Q; Canaud G
Med Sci (Paris); 2020 Mar; 36(3):235-242. PubMed ID: 32228842
[TBL] [Abstract][Full Text] [Related]
2. Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies.
Chacon-Camacho OF; Lopez-Moreno D; Morales-Sanchez MA; Hofmann E; Pacheco-Quito M; Wieland I; Cortes-Gonzalez V; Villanueva-Mendoza C; Zenker M; Zenteno JC
Mol Genet Genomic Med; 2019 May; 7(5):e625. PubMed ID: 30891959
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing aids diagnosis and management in a case of encephalocraniocutaneous lipomatosis.
Barry KK; Liang MG; Balkin DM; Srivastava S; Church AJ; Eng W
Pediatr Dermatol; 2024; 41(1):76-79. PubMed ID: 37486073
[TBL] [Abstract][Full Text] [Related]
4. Overgrowth. Section VI. Genetic syndromes and other disorders associated with overgrowth.
Sotos JF
Clin Pediatr (Phila); 1997 Mar; 36(3):157-70. PubMed ID: 9078418
[No Abstract] [Full Text] [Related]
5. RASopathies.
Jafry M; Sidbury R
Clin Dermatol; 2020; 38(4):455-461. PubMed ID: 32972603
[TBL] [Abstract][Full Text] [Related]
6. Encephalocraniocutaneous Lipomatosis Without Ocular Malformations.
Radić Nišević J; Prpić I; Antulov R; Sasso A; Holjar Erlić I
Pediatr Neurol; 2016 Jul; 60():71-4. PubMed ID: 27131628
[TBL] [Abstract][Full Text] [Related]
7. A postzygotic KRAS mutation in a patient with Schimmelpenning syndrome presenting with lipomatosis, renovascular hypertension, and diabetes mellitus.
Nagatsuma M; Takasawa K; Yamauchi T; Nakagawa R; Mizuno T; Tanaka E; Yamamoto K; Uemura N; Kashimada K; Morio T
J Hum Genet; 2019 Feb; 64(2):177-181. PubMed ID: 30443000
[TBL] [Abstract][Full Text] [Related]
8. Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas.
Valera ET; McConechy MK; Gayden T; Rivera B; Jones DTW; Wittmann A; Han H; Bareke E; Nikbakht H; Mikael L; Queiroz RG; Suazo VK; Phi JH; Kim SK; Park SH; Fukaya R; Yum MS; Ko TS; de Oliveira RS; Machado HR; Brassesco MS; do Santos AC; Simão GN; Ramalho LNZ; Neder L; Scrideli CA; Tone LG; Majewski J; Jabado N
Acta Neuropathol; 2018 Oct; 136(4):657-660. PubMed ID: 30143858
[No Abstract] [Full Text] [Related]
9. Whole-exome sequencing reveals causative genetic variants for several overgrowth syndromes in molecularly negative Beckwith-Wiedemann spectrum.
Higashimoto K; Sun F; Imagawa E; Saida K; Miyake N; Hara S; Yatsuki H; Kubiura-Ichimaru M; Fujita A; Mizuguchi T; Matsumoto N; Soejima H
J Med Genet; 2024 May; 61(6):590-594. PubMed ID: 38228391
[No Abstract] [Full Text] [Related]
10. Advances in overgrowth syndromes: clinical classification to molecular delineation in Sotos syndrome and Beckwith-Wiedemann syndrome.
Cytrynbaum CS; Smith AC; Rubin T; Weksberg R
Curr Opin Pediatr; 2005 Dec; 17(6):740-6. PubMed ID: 16282780
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging Findings in Encephalocraniocutaneous Lipomatosis.
Michael GA; Poretti A; Huisman TA
Pediatr Neurol; 2015 Nov; 53(5):462-3. PubMed ID: 26344330
[No Abstract] [Full Text] [Related]
13. Genetic considerations in the prenatal diagnosis of overgrowth syndromes.
Vora N; Bianchi DW
Prenat Diagn; 2009 Oct; 29(10):923-9. PubMed ID: 19609940
[TBL] [Abstract][Full Text] [Related]
14. Overgrowth syndromes with complex vascular anomalies.
Uller W; Fishman SJ; Alomari AI
Semin Pediatr Surg; 2014 Aug; 23(4):208-15. PubMed ID: 25241100
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnosis of somatic overgrowth conditions: A single-center experience.
Lalonde E; Ebrahimzadeh J; Rafferty K; Richards-Yutz J; Grant R; Toorens E; Marie Rosado J; Schindewolf E; Ganguly T; Kalish JM; Deardorff MA; Ganguly A
Mol Genet Genomic Med; 2019 Mar; 7(3):e536. PubMed ID: 30761771
[TBL] [Abstract][Full Text] [Related]
16. Somatic KRAS mutation affecting codon 146 in linear sebaceous nevus syndrome.
Kapoor S; Scanga HL; Reyes-Múgica M; Nischal KK
Am J Med Genet A; 2021 Dec; 185(12):3825-3830. PubMed ID: 34254724
[TBL] [Abstract][Full Text] [Related]
17. Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal syndrome and encephalocraniocutaneous lipomatosis.
Boppudi S; Bögershausen N; Hove HB; Percin EF; Aslan D; Dvorsky R; Kayhan G; Li Y; Cursiefen C; Tantcheva-Poor I; Toft PB; Bartsch O; Lissewski C; Wieland I; Jakubiczka S; Wollnik B; Ahmadian MR; Heindl LM; Zenker M
Clin Genet; 2016 Oct; 90(4):334-42. PubMed ID: 26970110
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Abdolrahimzadeh S; Scavella V; Felli L; Cruciani F; Contestabile MT; Recupero SM
Biomed Res Int; 2015; 2015():786519. PubMed ID: 26451379
[TBL] [Abstract][Full Text] [Related]
19. Genetic aspects of neurocutaneous disorders.
Jentarra G; Snyder SL; Narayanan V
Semin Pediatr Neurol; 2006 Mar; 13(1):43-7. PubMed ID: 16818175
[TBL] [Abstract][Full Text] [Related]
20. Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing.
Rasmussen M; Sunde L; Weigert KP; Bogaard PW; Lildballe DL
Am J Med Genet A; 2014 May; 164A(5):1318-21. PubMed ID: 24665065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
